Meeting
2023 ASCO Quality Care Symposium
Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II.
Authors
Mehmet Asim Bilen
Winship Cancer Institute of Emory University, Atlanta, GA
Mehmet Asim Bilen, Brandon Diessner, Valerie A. Morris, John White, Melissa Kirker, Amy Sainski-Nguyen, Norbek Gharibian, Louise Murphy, Abhijeet Bhanegaonkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 529)
DOI
10.1200/OP.2023.19.11_suppl.529
Abstract #
529
Poster Bd #
L4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Treatment trends for metastatic urothelial carcinoma across eight Mexican centers: A global oncology perspective.
First Author: Evelyn Lilian Beas-Lozano
Poster
2022 ASCO Genitourinary Cancers Symposium
Criteria used to determine platinum eligibility and first-line (1L) treatment (tx) patterns among platinum-eligible (PE) and -ineligible (PI) patients (pts) with metastatic urothelial cancer (mUC) in France, Germany, Spain, Italy, and the United Kingdom (Eu5).
First Author: Neil Milloy
Poster
2021 ASCO Annual Meeting
Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.
First Author: Daniel M. Geynisman
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron